Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute Myocardial Infarction and its Impact on Health Status

被引:81
作者
Amin, Amit P. [1 ,2 ]
Bachuwar, Alok [1 ,2 ]
Reid, Kimberly J. [3 ]
Chhatriwalla, Adnan K. [3 ,4 ]
Salisbury, Adam C. [3 ,4 ]
Yeh, Robert W. [5 ]
Kosiborod, Mikhail [3 ,4 ]
Wang, Tracy Y. [6 ]
Alexander, Karen P. [6 ]
Gosch, Kensey [3 ]
Cohen, David J. [3 ,4 ]
Spertus, John A. [3 ,4 ]
Bach, Richard G. [1 ,2 ]
机构
[1] Washington Univ, Cardiovasc Div, Sch Med, St Louis, MO 63110 USA
[2] Barnes Jewish Hosp, St Louis, MO 63110 USA
[3] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[4] Univ Missouri, Kansas City, MO 64110 USA
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA
[6] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
clopidogrel; dual antiplatelet therapy; EuroQOL; nuisance bleeding; quality of life; ACUTE CORONARY SYNDROMES; ST-SEGMENT-ELEVATION; RANDOMIZED MULTICENTER TRIAL; ADVERSE OUTCOMES; CLOPIDOGREL; INTERVENTION; PREDICTORS; REGISTRY; RISK; PCI;
D O I
10.1016/j.jacc.2013.02.044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to examine the incidence of nuisance bleeding after AMI and its impact on QOL. Background Prolonged dual antiplatelet therapy (DAPT) is recommended after acute myocardial infarction (AMI) to reduce ischemic events, but it is associated with increased rates of major and minor bleeding. The incidence of even lesser degrees of post-discharge "nuisance" bleeding with DAPT and its impact on quality of life (QOL) are unknown. Methods Data from the 24-center TRIUMPH (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) study of 3,560 patients, who were interviewed at 1, 6, and 12 months after AMI, were used to investigate the incidence of nuisance bleeding (defined as Bleeding Academic Research Consortium type 1). Baseline characteristics associated with "nuisance" bleeding and its association with QOL, as measured by the EuroQol 5 Dimension visual analog scale, and subsequent re-hospitalization were examined. Results Nuisance (Bleeding Academic Research Consortium type 1) bleeding occurred in 1,335 patients (37.5%) over the 12 months after AMI. After adjusting for baseline bleeding and mortality risk, ongoing DAPT was the strongest predictor of nuisance bleeding (rate ratio [RR]: 1.44, 95% confidence interval [CI]: 1.17 to 1.76 at 1 month; RR: 1.89, 95% CI: 1.35 to 2.65 at 6 months; and RR: 1.39, 95% CI: 1.08 to 1.79 at 12 months; p < 0.01 for all comparisons). Nuisance bleeding at 1 month was independently associated with a decrement in QOL at 1 month (-2.81 points on EuroQol 5 Dimension visual analog scale; 95% CI: 1.09 to 5.64) and nonsignificantly toward higher re-hospitalization (hazard ratio: 1.20; 95% CI: 0.95 to 1.52). Conclusions Nuisance bleeding is common in the year after AMI, associated with ongoing use of DAPT, and independently associated with worse QOL. Improved selection of patients for prolonged DAPT may help minimize the incidence and adverse consequences of nuisance bleeding. (C) 2013 by the American College of Cardiology Foundation
引用
收藏
页码:2130 / 2138
页数:9
相关论文
共 31 条
[1]   Evaluating the Performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) Bleeding Score in a Contemporary Spanish Cohort of Patients With Non-ST-Segment Elevation Acute Myocardial Infarction [J].
Abu-Assi, Emad ;
Maria Gracia-Acuna, Jose ;
Ferreira-Gonzalez, Ignacio ;
Pena-Gil, Carlos ;
Gayoso-Diz, Pilar ;
Ramon Gonzalez-Juanatey, Jose .
CIRCULATION, 2010, 121 (22) :2419-U100
[2]   Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) Design and Rationale of a Prospective Multicenter Registry [J].
Arnold, Suzanne V. ;
Chan, Paul S. ;
Jones, Philip G. ;
Decker, Carole ;
Buchanan, Donna M. ;
Krumholz, Harlan M. ;
Ho, P. Michael ;
Spertus, John A. .
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2011, 4 (04) :467-476
[3]   Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial [J].
Becker, Richard C. ;
Bassand, Jean Pierre ;
Budaj, Andrzej ;
Wojdyla, Daniel M. ;
James, Stefan K. ;
Cornel, Jan H. ;
French, John ;
Held, Claes ;
Horrow, Jay ;
Husted, Steen ;
Lopez-Sendon, Jose ;
Lassila, Riitta ;
Mahaffey, Kenneth W. ;
Storey, Robert F. ;
Harrington, Robert A. ;
Wallentin, Lars .
EUROPEAN HEART JOURNAL, 2011, 32 (23) :2933-2944
[4]   Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents [J].
Ben-Dor, Itsik ;
Torguson, Rebecca ;
Scheinowitz, Mickey ;
Li, Yanlin ;
Delhaye, Cedric ;
Wakabayashi, Kohei ;
Maluenda, Gabriel ;
Syed, Asmir I. ;
Collins, Sara D. ;
Gonzalez, Manuel A. ;
Gaglia, Michael A., Jr. ;
Xue, Zhenyi ;
Kaneshige, Kimberly ;
Satler, Lowell F. ;
Suddath, William O. ;
Kent, Kenneth M. ;
Pichard, Augusto D. ;
Waksman, Ron .
AMERICAN HEART JOURNAL, 2010, 159 (05) :871-875
[5]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[6]  
Decker Carole, 2008, Patient Prefer Adherence, V2, P167
[7]   Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture [J].
Dhillon, V ;
Hurst, N ;
Hannan, J ;
Nuki, G .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (05) :483-489
[8]   A validated prediction model for all forms of acute coronary syndrome - Estimating the risk of 6-month postdischarge death in an international registry [J].
Eagle, KA ;
Lim, MJ ;
Dabbous, OH ;
Pieper, KS ;
Goldberg, RJ ;
Van de Werf, F ;
Goodman, SG ;
Granger, CB ;
Steg, PG ;
Gore, JM ;
Budaj, A ;
Avezum, A ;
Flather, MD ;
Fox, KAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (22) :2727-2733
[9]   Validation of the EQ-5D in patients with a history of acute coronary syndrome [J].
Ellis, JJ ;
Eagle, KA ;
Kline-Rogers, EM ;
Erickson, SR .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (08) :1209-1216
[10]   Clinician-patient discord: Exploring differences in perspectives for discontinuing clopidogrel [J].
Garavalia, Linda ;
Ho, P. Michael ;
Garavalia, Brian ;
Foody, JoAnne M. ;
Kruse, Heather ;
Spertus, John A. ;
Decker, Carole .
EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2011, 10 (01) :50-55